AFT Pharmaceuticals - Pascomer falls short of FDA mandated threshold
AFT Pharmaceuticals announced that its Pascomer Phase II clinical trial has failed to meet its primary endpoint of a two-point improvement on the...
796 Views
AFT Pharmaceuticals - Expanding reach into China
AFT Pharmaceuticals has announced the online launch of a wider range of its over-the-counter (OTC) medicines in China following registration under...
768 Views
AFT Pharmaceuticals - Maxigesic IV hits a roadblock in the US
In an unexpected development, AFT Pharmaceuticals (AFT) has announced that it has received a complete response letter (CRL) from the United States...
729 Views
AFT Pharmaceuticals - Re-acceleration leveraging its platform
Overcoming COVID-19 headwinds, AFT Pharmaceuticals reported strong FY22 year results, largely driven by management’s ability to leverage its broad...
750 Views
AFT Pharmaceuticals - Recovery driven by strong H222
AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid...
725 Views